Ibnsina Pharma (CAI:ISPH) ROCE %: 63.42% (As of Mar. 2026)


CAI:ISPH Ibnsina Pharma CAI:ISPH
85 GF Score
Price E£11.67
GF Value E£10.46
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma ROCE %?

Ibnsina Pharma CAI:ISPH +1.92% 85 ROCE % is 63.42% as of Mar. 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.46 (Modestly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ibnsina Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was 63.42%.

Ibnsina Pharma  (CAI:ISPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ibnsina Pharma ROCE % Related Terms

Ibnsina Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Ibnsina Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ibnsina Pharma ROCE % Chart

Ibnsina Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.56 30.51 52.28 81.83 94.49

Ibnsina Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.21 112.20 113.24 99.05 63.42
CAI:ISPH
85GF Score
Ibnsina Pharma CAI:ISPH
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ibnsina Pharma ROCE % Calculation

Ibnsina Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=3635.958/( ( (28641.558 - 25427.089) + (36213.704 - 31732.37) )/ 2 )
=3635.958/( (3214.469+4481.334)/ 2 )
=3635.958/3847.9015
=94.49 %

Ibnsina Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=2981.32/( ( (36213.704 - 31732.37) + (39166.759 - 34245.628) )/ 2 )
=2981.32/( ( 4481.334 + 4921.131 )/ 2 )
=2981.32/4701.2325
=63.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 63.42% mean?
Ibnsina Pharma (CAI:ISPH) has a ROCE % of 63.42% as of Mar. 2026.
Is Ibnsina Pharma's ROCE % too high?
Ibnsina Pharma's current ROCE % is 63.42%. The Medical Distribution industry median ROCE % is 9.09. Ibnsina Pharma's value of 63.42% is 597.7% above this industry median. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's ROCE % compare to MCK and CAH?
Ibnsina Pharma's ROCE % of 63.42% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.09. Ibnsina Pharma's value of 63.42% is 597.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.09, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current ROCE % of 63.42% is 597.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current ROCE % is 63.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.46, compared to a current price of E£11.67 — trading 11.6% above its estimated fair value. The current ROCE % is 63.42% and 597.7% above the Medical Distribution industry median of 9.09. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current ROCE % is 63.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£11.67 is trading 11.6% above its estimated GF Value™ of E£10.46. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • ROCE %: 63.42%
  • GF Value™: E£10.46 vs. price of E£11.67 (11.6% above fair value)
  • GF Score™: 85/100 with 7 warning signs
  • Industry Position: 597.7% above the Medical Distribution median

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score

Get the complete analysis for CAI:ISPH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£11.67
Price
E£10.46
GF Value